The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Interventions for rosacea
Open accessAbstract
BACKGROUND: Rosacea is a common chronic skin condition affecting the face, characterised by flushing, redness, pimples, pustules and dilated blood vessels. The eyes are often involved and thickening of the skin with enlargement (phymas), especially of the nose, can occur in some people. A range of treatment options are available but it is unclear which are most effective. OBJECTIVES: To assess the efficacy and safety of treatments for rosacea. SEARCH METHODS: We updated our searches, to July 2014, of: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library (2014, Issue 6), MEDLINE (from 1946), EMBASE (from 1974) and Science Citation Index (from 1988). We searched five trials registers and checked reference lists for further relevant studies. SELECTION CRITERIA: Randomised controlled trials in people with moderate to severe rosacea. DATA COLLECTION AND ANALYSIS: Study selection, data extraction, risk of bias assessment and analyses were carried out independently by two authors. MAIN RESULTS: We included 106 studies, comprising 13,631 participants. Sample sizes of 30-100 and study duration of two to three months were most common. More women than men were included, mean age of 48.6 years, and the majority had papulopustular rosacea, followed by erythematotelangiectatic rosacea.A wide range of comparisons (67) were evaluated. Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral antibiotics, combinations with topical treatments or other systemic treatments, i.e. isotretinoin. Several studies evaluated laser or light-based treatment.The majority of studies (57/106) were assessed as 'unclear risk of bias', 37 'high risk ' and 12 'low risk'. Twenty-two studies provided no usable or retrievable data i.e. none of our outcomes were addressed, no separate data reported for rosacea or limited data in abstracts.Eleven studies assessed our primary outcome 'change in quality of life', 52 studies participant-assessed changes in rosacea severity and almost all studies addressed adverse events, although often only limited data were provided. In most comparisons there were no statistically significant differences in number of adverse events, most were mild and transient. Physician assessments including investigators' global assessments, lesion counts and erythema were evaluated in three-quarters of the studies, but time needed for improvement and duration of remission were incompletely or not reported.The quality of the body of evidence was rated moderate to high for most outcomes, but for some outcomes low to very low.Data for several outcomes could only be pooled for topical metronidazole and azelaic acid. Both were shown to be more effective than placebo in papulopustular rosacea (moderate quality evidence for metronidazole and high for azelaic acid). Pooled data from physician assessments in three trials demonstrated that metronidazole was more effective compared to placebo (risk ratio (RR) 1.98, 95% confidence interval (CI) 1.29 to 3.02). Four trials provided data on participants' assessments, illustrating that azelaic acid was more effective than placebo (RR 1.46, 95% CI 1.30 to 1.63). The results from three studies were contradictory on which of these two treatments was most effective.Two studies showed a statistically significant and clinically important improvement in favour of topical ivermectin when compared to placebo (high quality evidence). Participants' assessments in these studies showed a RR of 1.78 (95% CI 1.50 to 2.11) and RR of 1.92 (95% CI 1.59 to 2.32),which were supported by physicians' assessments. Topical ivermectin appeared to be slightly more effective than topical metronidazole for papulopustular rosacea, based on one study, for improving quality of life and participant and physician assessed outcomes (high quality evidence for these outcomes).Topical brimonidine in two studies was more effective than vehicle in reducing erythema in rosacea at all time points over 12 hours (high quality evidence). At three hours the participants' assessments had a RR of 2.21 (95% CI 1.52 to 3.22) and RR of 2.00 (95% CI 1.33 to 3.01) in favour of brimonidine. Physicians' assessments confirmed these data. There was no rebound or worsening of erythema after treatment cessation.Topical clindamycin phosphate combined with tretinoin was not considered to be effective compared to placebo (moderate quality evidence).Topical ciclosporin ophthalmic emulsion demonstrated effectiveness and improved quality of life for people with ocular rosacea (low quality evidence).Of the comparisons assessing oral treatments for papulopustular rosacea there was moderate quality evidence that tetracycline was effective but this was based on two old studies of short duration. Physician-based assessments in two trials indicated that doxycycline appeared to be significantly more effective than placebo (RR 1.59, 95% CI 1.02 to 2.47 and RR 2.37,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Wilkin, J., Dahl, M., Detmar, M., Drake, L., Feinstein, A., Odom, R., & Powell, F. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120625 · Cited by 917
Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea
Yamasaki, K., Di Nardo, A., Bardan, A., Murakami, M., Ohtake, T., Coda, A., Dorschner, R. A., Bonnart, C., Descargues, P., Hovnanian, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1616 · Cited by 852
Basra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Tetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Chren, M.-M., Lasek, R. J., Quinn, L. M., Mostow, E. N., & Zyzanski, S. J. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12365600 · Cited by 699
Wilkin, J., Dahl, M., Detmar, M., Drake, L., Liang, M. H., Odom, R., & Powell, F. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.01.048 · Cited by 429
New insights into rosacea pathophysiology: A review of recent findings
Steinhoff, M., Schauber, J., & Leyden, J. J. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.04.045 · Cited by 385
Mite-related bacterial antigens stimulate inflammatory cells in rosacea
Lacey, N., Delaney, S., Kavanagh, K., & Powell, F. C. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08028.x · Cited by 313
Clinical, Cellular, and Molecular Aspects in the Pathophysiology of Rosacea
Steinhoff, M., Buddenkotte, J., Aubert, J., Sulk, M., Novak, P., Schwab, V. D., Mess, C., Cevikbas, F., Rivier, M., Carlavan, I., et al. (2011) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2011.7 · Cited by 281
SINGLE SOLUTION FOR ORAL THERAPY OF DIARRHŒA
Hirschhorn, N. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90351-7 · Cited by 281
Powell, F. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042829 · Cited by 262
Rosacea: Current state of epidemiology
Tan, J., & Berg, M. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.04.043 · Cited by 262
Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication
Parodi, A., Paolino, S., Greco, A., Drago, F., Mansi, C., Rebora, A., Parodi, A., & Savarino, V. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.054 · Cited by 225
Del Rosso, J. Q., Webster, G. F., Jackson, M., Rendon, M., Rich, P., Torok, H., & Bradshaw, M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.11.021 · Cited by 224
Elewski, B., Draelos, Z., Dréno, B., Jansen, T., Layton, A., & Picardo, M. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03751.x · Cited by 207
Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link
Forton, F. M. N. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04310.x · Cited by 186
Rosacea as a Disease of Cathelicidins and Skin Innate Immunity
Yamasaki, K., & Gallo, R. L. (2011) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2011.4 · Cited by 182
The psychological impact of rosacea and the influence of current management options
Moustafa, F., Lewallen, R. S., & Feldman, S. R. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.036 · Cited by 180
Taieb, A., Ortonne, J. P., Ruzicka, T., Roszkiewicz, J., Berth-Jones, J., Peirone, M. H., Jacovella, J., & the Ivermectin Phase III study group (2015) · British Journal of Dermatology · doi:10.1111/bjd.13408 · Cited by 178
Fowler, J., Jarratt, M., Moore, A., Meadows, K., Pollack, A., Steinhoff, M., Liu, Y., Leoni, M., & on behalf of the Brimonidine Phase II Study Group (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10716.x · Cited by 167
Rosacea: Pathophysiology and Treatment
Wilkin, J. K. (1994) · Archives of Dermatology · doi:10.1001/archderm.1994.01690030091015 · Cited by 165
Stein, L. F., Kircik, L., Fowler, J. F., Tan, J. K. L., Draelos, Z. D., Fleischer, A. B., Appell, M. L., Steinhoff, M. S., Lynde, C. W., Liu, H., et al. (2014) · PubMed · Cited by 162
Thiboutot, D., Thieroff-Ekerdt, R., & Graupe, K. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.308 · Cited by 160
Reliability of Clinician Erythema Assessment grading scale
Tan, J. K. L., Liu, H., Leyden, J. J., & Leoni, M. J. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.044 · Cited by 156
The use and safety of doxycycline hyclate and other second-generation tetracyclines
Sloan, B., & Scheinfeld, N. S. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.5.571 · Cited by 150
Elewski, B. E., Fleischer, A. B., & Pariser, D. M. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.11.1444 · Cited by 133
Gollnick, H. P. M., Blume‐Peytavi, U., Szabó, E. L., Meyer, K., Hauptmann, P., Popp, G., Sebastian, M., Zwingers, T., Willers, C. P., & von der Weth, R. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07345.x · Cited by 118
Maddin, S. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70085-x · Cited by 116
A Comparison of the Efficacy of Topical Tretinoin and Low-Dose Oral Isotretinoin in Rosacea
Ertl, G., Levine, N., & Kligman, A. M. (1994) · Archives of Dermatology · doi:10.1001/archderm.1994.01690030051008 · Cited by 115
Topical antifungal treatments for tinea cruris and tinea corporis
El-Gohary, M., van Zuuren, E. J., Fedorowicz, Z., Burgess, H., Doney, L., Stuart, B. L., Moore, M. V., & Little, P. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009992.pub2 · Cited by 112
Self-citationTopical Metronidazole Therapy for Rosacea
Bleicher, P. A. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.5.609 · Cited by 110
Effect of Treatment of Helicobacter pylori Infection on Rosacea
Bamford, J. T. M., Tilden, R. L., Blankush, J. L., & Gangeness, D. E. (1999) · Archives of Dermatology · doi:10.1001/archderm.135.6.659 · Cited by 109
A pilot quality-of-life instrument for acne rosacea
Nicholson, K. M., Abramova, L., Chren, M., Yeung, J., Chon, S. Y., & Chen, S. C. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.01.048 · Cited by 107
Shanler, S. D. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.11.1369 · Cited by 104
Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea.
Draelos, Z. D., Ertel, K. D., & Berge, C. A. (2005) · PubMed · Cited by 103
Akhyani, M., Ehsani, A. H., Ghiasi, M., & Jafari, A. (2008) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.03445.x · Cited by 98
Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard Item
Bero, L. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000075 · Cited by 98
Understanding the burden of adult female acne.
Tanghetti, E. A., Kawata, A. K., Daniels, S. R., Yeomans, K., Burk, C. T., & Callender, V. D. (2014) · Europe PMC (PubMed Central) · Cited by 97
Rosso, J. Q. D., Schlessinger, J., & Werschler, P. (2008) · PubMed · Cited by 94
Efficacy of topical cyclosporine for the treatment of ocular rosacea
Schechter, B. A., Katz, R., & Friedman, L. S. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0037-2 · Cited by 94
A system for rating the stability and strength of medical evidence
Treadwell, J. R., Tregear, S. J., Reston, J. T., & Turkelson, C. M. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-52 · Cited by 93
Oxidative stress and ferritin expression in the skin of patients with rosacea
Tišma, V. S., Basta-Juzbašić, A., Jaganjac, M., Brčić, L., Dobrić, I., Lipozenčić, J., Tatzber, F., Žarković, N., & Poljak‐Blaži, M. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.10.014 · Cited by 92
Current topical and systemic approaches to treatment of rosacea
Hc, K., & Schöllmann, C. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03167.x · Cited by 90
Systematic review of rosacea treatments
van Zuuren, E. J., Gupta, A. K., Gover, M. D., Graber, M. A., & Hollis, S. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.084 · Cited by 87
The quality of life impact of acne and rosacea compared to other major medical conditions.
Cresce, N. D., Davis, S. A., Huang, W. W.-T., & Feldman, S. R. (2014) · PubMed · Cited by 84
Rosso, J. Q. D. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.009 · Cited by 81
Sánchez, J., Lugo‐Somolinos, A., Almodóvar, P. I., WEBSTER, G. F., Bradshaw, M. H., & Powala, C. V. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.04.069 · Cited by 79
Culp, B. L., & Scheinfeld, N. S. (2009) · Europe PMC (PubMed Central) · Cited by 78
Dahl, M. V., Jarratt, M., Kaplan, D., et al. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.116219 · Cited by 77
Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review
van der Linden, M. M. D., van Rappard, D. C., Daams, J. G., et al. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-1976 · Cited by 72
Rosacea and its ocular manifestations
Oltz, M., & Check, J. (2011) · Optometry · doi:10.1016/j.optm.2010.01.015 · Cited by 71
Subantimicrobial Dose Doxycycline for Acne and Rosacea
Bikowski Joseph, B. (2003) · SKINmed Dermatology for the Clinician · doi:10.1111/j.1540-9740.2003.03014.x · Cited by 69
TREATMENT OF ROSACEA: TOPICAL CLINDAMYCIN VERSUS ORAL TETRACYCLINE
Wilkin, J. K., & DeWitt, S. (1993) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1993.tb00974.x · Cited by 69
Adapalene vs. metronidazole gel for the treatment of rosacea
Altinyazar, H. C., Koca, R., Tekin, N. S., & Hazinedar, E. (2004) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2004.02130.x · Cited by 68
Rosso, J. Q. D. (2012) · Europe PMC (PubMed Central) · Cited by 68
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial
Weissenbacher, S., Merkl, J., Hildebrandt, B., Wollenberg, A., Braeutigam, M., Ring, J., & Hofmann, H. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07669.x · Cited by 66
Interventions for female pattern hair loss
van Zuuren, E. J., Fedorowicz, Z., Carter, B., Andriolo, R. B., & Schoones, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007628.pub3 · Cited by 64
Self-citationScavenging properties of metronidazole on free oxygen radicals in a skin lipid model system
Narayanan, S., Huenerbein, A., Getie, M., Jäckel, A., & Neubert, R. H. H. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.8.0010 · Cited by 63
Oral Tetracyclines for Ocular Rosacea: An Evidence-Based Review of the Literature
Stone, D. U., & Chodosh, J. (2003) · Cornea · doi:10.1097/00003226-200401000-00020 · Cited by 61
Oral zinc sulfate in the treatment of rosacea: A double-blind, placebo-controlled study
Sharquie, K. E., Najim, R. A., & Al‐Salman, H. N. (2006) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2006.02944.x · Cited by 59
Breneman, D., Savin, R. P., VandePol, C. J., Vamvakias, G., Levy, S. F., & Leyden, J. (2004) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2004.02283.x · Cited by 58
van Zuuren, E. J., Kramer, S. F., Carter, B., Graber, M. A., & Fedorowicz, Z. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003262.pub4 · Cited by 54
Self-citationRapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis
Nadiminti, U., & Arbiser, J. L. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.05.044 · Cited by 53
Dn, S., Miller, R., Gratton, D., Danby, W., Griffiths, C. E. M., & Phillips, S. (1997) · Journal of Dermatological Treatment · doi:10.3109/09546639709160276 · Cited by 52
The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea
Chu, C. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06404.x · Cited by 50
Alcohol-induced rosacea flushing blocked by naloxone
Bernstein, J. E., & Soltani, K. (1982) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1982.tb00290.x · Cited by 49
Berardesca, E., Cameli, N., Cavallotti, C., Levy, J. L., Pierard, G., & Paoli, G. D. (2008) · Journal of Cosmetic Dermatology · doi:10.1111/j.1473-2165.2008.00355.x · Cited by 48
Karabulut, A., Serel, B. I., & Eksioglu, H. (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02589.x · Cited by 47
Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea
Bamford, J. T. M., Gessert, C. E., Haller, I. V., Kruger, K., & Johnson, B. P. (2012) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.05353.x · Cited by 47
Draelos, Z. D., Hornby, S. B., Walters, R. M., & Appa, Y. (2013) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.12061 · Cited by 46
Two, A. M., Hata, T. R., Nakatsuji, T., Coda, A. B., Kotol, P. F., Wu, W., Shafiq, F., Huang, E. Y., & Gallo, R. L. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.472 · Cited by 46
Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.
Nickle, S. B., Peterson, N., & Peterson, M. (2014) · Europe PMC (PubMed Central) · Cited by 46
Lee, D. H., Li, K., & Suh, D. H. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08496.x · Cited by 42
Uslu, M., Åžavk, E., Karaman, G., & Åžendur, N. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1204 · Cited by 40
Laquieze, S., Czernielewski, J., & Baltás, E. (2007) · Journal of Dermatological Treatment · doi:10.1080/09546630601121078 · Cited by 39
Measuring the severity of rosacea: a review
Gessert, C. E., & Bamford, J. T. M. (2003) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2003.01780.x · Cited by 35
Shim, T. N., & Abdullah, A. (2013) · Europe PMC (PubMed Central) · Cited by 32
Oral Spironolactone Therapy in Male Patients with Rosacea
Aizawa, H., & Niimura, M. (1992) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1992.tb03227.x · Cited by 32
Jackson, J. M., Fowler, J. F., Moore, A. Y., et al. (2014) · PubMed · Cited by 28
Current Drug Therapies for Rosacea: A Chronic Vascular and Inflammatory Skin Disease
Feldman, S. R., Huang, W. W.-T., & Huynh, T. T. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.6.623 · Cited by 25
Määttã, M., Kari, O., Tervahartiala, T. I., et al. (2008) · Cornea · doi:10.1097/ico.0b013e31815c18d6 · Cited by 22
Comparative study of some treatment modalities of rosacea
Mostafa, F., HARRAS, M. E., Gomaa, S., Mokadem, S. A., Nassar, A., & Gawad, E. A. (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02940.x · Cited by 21
Togsverd‐Bo, K., Wiegell, S. R., Wulf, H., & Hædersdal, M. (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02781.x · Cited by 20
Chang, A. L. S., Alora-Palli, M. B., Lima, X. T. V., Chang, T. C., Cheng, C. E., Chung, C. M., Amir, O., & Kimball, A. B. (2012) · PubMed · Cited by 18
Cited by
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Schaller, M., Almeida, L. M. C., Bewley, A., Cribier, B., Del Rosso, J., Dlova, N. C., Gallo, R. L., Granstein, R. D., Kautz, G., Mannis, M. J., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18420 · Cited by 253
Barraza, G. A., Castro-Guijarro, A. C., de la Fuente Hoffmann, V., Bolívar Ávila, S. J., Flamini, M. I., & Sanchez, A. M. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108988 · Cited by 9
Metadata
- Authors
- van Zuuren, E. J., Fedorowicz, Z., Carter, B., van der Linden, M. M., & Charland, L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-04-28
- Volume
- 2017
- Issue
- 5
- Pages
- CD003262-CD003262
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2160443131
- Cited by
- 269
- References
- 88
- FWCI
- 29.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.